Background: Methylation on the fifth position of cytosine (5-mC) is an essential epigenetic mark that is linked to both normal neurodevelopment and neurological diseases. The recent identification of another modified form of cytosine, 5-hydroxymethylcytosine (5-hmC), in both stem cells and post-mitotic neurons, raises new questions as to the role of this base in mediating epigenetic effects. Genomic studies of these marks using model systems are limited, particularly with array-based tools, because the standard method of detecting DNA methylation cannot distinguish between 5-mC and 5-hmC and most methods have been developed to only survey the human genome. Results: We show that non-human data generated using the optimization of a widely used human DNA methylation array, designed only to detect 5-mC, reproducibly distinguishes tissue types within and between chimpanzee, rhesus, and mouse, with correlations near the human DNA level (R 2 > 0.99). Genome-wide methylation analysis, using this approach, reveals 6,102 differentially methylated loci between rhesus placental and fetal tissues with pathways analysis significantly overrepresented for developmental processes. Restricting the analysis to oncogenes and tumor suppressor genes finds 76 differentially methylated loci, suggesting that rhesus placental tissue carries a cancer epigenetic signature. Similarly, adapting the assay to detect 5-hmC finds highly reproducible 5-hmC levels within human, rhesus, and mouse brain tissue that is species-specific with a hierarchical abundance among the three species (human > rhesus >> mouse). Annotation of 5-hmC with respect to gene structure reveals a significant prevalence in the 3'UTR and an association with chromatin-related ontological terms, suggesting an epigenetic feedback loop mechanism for 5-hmC. Conclusions: Together, these data show that this array-based methylation assay is generalizable to all mammals for the detection of both 5-mC and 5-hmC, greatly improving the utility of mammalian model systems to study the role of epigenetics in human health, disease, and evolution.
Background DNA methylation and histone modifications are essential epigenetic components in the establishment of the transcriptional state of eukaryotic genes throughout the genome. The best understood of these epigenetic modifications is DNA methylation, which occurs primarily at cytosines located 5' to guanosine in the CpG dinucleotide of differentiated eukaryotic nuclei [1] . This modification is less common in CpG-rich areas, known as CpG islands, which are often located in the promoter regions of many genes and involved in transcriptional regulation. While DNA methylation is a hallmark of human cancer [2] , the identification of a growing number of human diseases resulting from epigenetic disruptions emphasizes the importance of this mark [3] [4] [5] [6] [7] .
The recent identification of another modified form of cytosine, 5-hydroxymethylcytosine (5-hmC) , in both stem cells and post-mitotic neurons, raises new questions as to the role of this base in mediating epigenetic effects. 5-hmC is mediated by members of the ten-eleven translocation (TET) family of proteins, which each contain a Cterminal oxidase domain. Recently, a highly efficient and selective chemical approach to label and capture 5-hmC revealed the first distribution map of 5-hmC in a mammalian brain genome (mouse) and showed that 5-hmC is enriched in the gene bodies of active or highly transcribed genes [8] . Furthermore, acquisition of 5-hmC in specific gene bodies occurs during neuronal differentiation and maturation, indicating that this mark may be distributed in a spatial and temporal manner in brain during development.
Traditionally, non-human studies of DNA methylation have relied heavily on the 'gold standard' for DNA methylation detection: treatment of genomic DNA with sodium bisulfite, amplification of the gene (s)/region(s) of interest, and sequencing the resulting amplicons [9] . While this method is robust, it is subject to amplification biases and considered very laborious, allowing only for a limited number of sites to be interrogated at a time. The introduction of genome-wide arrays and 'Next-Generation' sequencing technologies permits genome-wide interrogation of 5-methylcytosine (5-mC) but these methodologies either focus solely on human studies (arrays), do not provide base resolution (enrichment techniques), or are cost prohibitive (whole genome sequencing). In addition, these methods could not distinguish between 5-mC and 5-hmC; however, numerous sequencing-based methods have recently emerged that now allow for the quantitative discrimination of the two modified bases [10, 11] . In this study we combined these recent 5-hmC detection methods with standard array-based methods to develop a novel use for the HumanMethylation450 BeadChip from Illumina to measure both 5-mC and 5-hmC in mammalian model systems.
Non-human primates (e.g. rhesus monkeys) and humans have structural and functional similarities in the neural circuits mediating neuropsychiatric disease. Access to relevant brain regions associated with neuropsychiatric disorders from a monkey model improves our ability to translate research findings to humans and provides opportunities to test hypotheses that cannot be tested in humans. However, genome-wide molecular approaches, such as array based assays, in non-human genomes have not matched resources aimed at the human genome. Here, we optimized an established human array that was originally designed to detect 5-mC levels at nearly half a million loci throughout the human genome and show that it is also capable of measuring genomewide DNA methylation levels in other species, including non-human primates and mice.
Results

Assay optimization
To overcome the paucity of molecular tools for DNA methylation detection in non-human primates, we optimized a highly reproducible and widely used human array [12] [13] [14] [15] [16] to measure genome-wide DNA methylation levels in rhesus macaque (Macaca mulatta). The human array is designed to provide a quantitative measure of 5-methylcytocine (DNA methylation; 5-mC) at 485,512 CpG dinucleotides located proximal to nearly all human RefSeq genes (N = 21,231). We interrogated each fifty nucleotide probe sequence on the array to determine the fraction that had either an exact match or up to four mismatches to the rhesus genome and found that approximately 7% and 30%, respectively, of the array probes met this criteria, (rhesus-competent probes; exact match: N = 35,901; mismatch: N = 154,030; Additional file 1; see Methods). We hypothesized that both sets of these rhesus-competent probes should reproducibly provide a quantitative measure of DNA methylation at the majority (exact match: > 55%, N = 11,804; mismatch > 90%, N = 19,362) of the human annotated RefSeq genes in the rhesus genome. Indeed filtering the array probes to only the rhesus-competent probes reduces the median number of CpG dinucleotides interrogated per gene from fifteen (human) to two or six (rhesus exact match or mismatch, respectively; Additional file 2A).
Using only the rhesus-competent probes, we tested the reproducibility of this array on monkey DNAs extracted from skin biopsies of two healthy monkeys and found that each monkey's replicates (N = 3) were highly correlated to each other regardless of the rhesus probe set (exact match or mismatch), with R 2 -values similar to those found among human replicates for this assay (R 2 > 0.99; Figure 1A -B). Notably, the methylation levels of the rhesus probes were significantly correlated to the levels found in humans ( Figure 1D ). Together, these data suggested that both rhesus-competent probe sets within this assay are capable of providing an accurate quantitative measure of DNA methylation throughout the rhesus genome. As a further test of this conclusion, we used only rhesus-competent probes with data passing stringent quality control (exact match: N = 35,750; mismatch: N = 148,850; Methods) and investigated whether the rhesus-competent probes were capable of distinguishing between placental and fetal (heart and liver) tissues from five pregnancies. This analysis revealed, regardless of probe set, a clear hierarchical distinction of placenta and fetal tissues, as well as between the two fetal tissues (Figure 2 ), indicating that the rhesus-competent probes have robust tissue-distinguishing properties similar to those found when the full set of array probes are used in human studies [17] . Finding that both rhesuscompetent probe sets generated correlations > 0.99 and tissue distinguishing hierarchical clusters that were nearly identical ( Figure 2 ) suggested that the use of both sets was redundant. While we conducted all subsequent analyses with both probe sets and found nearly identical results, we only present the data from the more comprehensive set of rhesus-competent probes, the mismatch set (N = 148,850).
Genome-wide DNA methylation analysis in rhesus macaque
Placental tissue has drawn biological and gene expression analogies to malignant tissues [18] [19] [20] [21] [22] . A recent study used the traditional DNA methylation detection method (locus-specific sodium bisulfite sequencing) to compare the promoter regions of nine tumor suppressor genes in placental and fetal tissue and only found hypermethylation in the promoter of the Ras association domain family 1 A (RASSF1A) gene [23] . We determined that there are several rhesus-competent probes (N = 117) residing throughout the nine tumor suppressor genes interrogated by Chiu et al. (Additional file 3) and that these probes were able to distinguish between all three tissue types, particularly the fetal from the placental tissues ( Figure 3A ). Thus, we conducted a linear mixed-effects regression analysis (see Methods) on this restricted set of probes and found differential methylation throughout RASSF1 (N = 10; Figure 3B and Additional file 3) and several of the other tumor suppressor genes previously tested (MGMT (N = 7), DAPK1 (N = 3), and CDKN2B (N = 2); Additional file 3). Indeed, this assay simultaneously interrogates additional regions that were not investigated by Chiu and colleagues, which underscores the more comprehensive potential of this assay for DNA methylation detection in the rhesus macaque genome. Independent analysis of sodium bisulfite converted DNA spanning the genomic region interrogated by this assay corresponded well with the β values generated by the array (Additional file 2C-G), again validating the accuracy of this array and this set of probes to measure DNA methylation levels in the rhesus genome.
To further explore the potential of this assay, we used the rhesus-competent probes to conduct a genome-wide regression analysis of methylation levels between placental and fetal tissue and identified 6,102 differentially methylated loci (Bonferroni <0.05; Additional file 4). To statistically validate our methods and adjust for possible failure of asymptotic assumptions due to the small sample size, we performed one hundred permutations of the data and found that there was a high correlation between the asymptotic P-values and the permuted P-values (Additional file 2B and Additional file 4; Methods). Annotation of the differentially methylated loci using gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathways revealed biologically relevant terms that were significantly overrepresented for developmental processes (Additional file 5). However, the KEGG analysis did not find an overrepresentation of cancer related terms, suggesting that normal tissue differentiation is the primary purpose of the different methylation marks. Nonetheless, we restricted the probes used in the regression analysis to those annotated to oncogenes and tumor suppressor genes and identified cancerspecific differentially methylated loci (N = 76; Additional file 6), suggesting placental tissue carries a cancer epigenetic signature.
Species-specific methylation marks
These findings led us to test the hypothesis that other species-competent probe sets could be identified and used to study genome-wide DNA methylation. Thus we conducted a similar probe analysis to identify competent probes for the mouse (N = 9,734; Additional file 1) and the chimpanzee (N = 360,491; Additional file 1). Using the mouse-competent probes, we tested the reproducibility of this array and found that each mouse's replicates (N = 3) were highly correlated to each other, with R 2 -values similar to those found among human and rhesus replicates for this assay (R 2 > 0.99; Figure 1 ). In addition, using each set of species-competent probes (human, chimpanzee, rhesus, and mouse), we compared the consistency of this array between individuals of the same species (N = 3) and showed that there is a similarly high consistency among individuals of the same species (mean R 2 > 0.90; Additional file 7), and that a set of common probes (N = 8,189) can clearly distinguish the species from one another (Additional file 8A). Furthermore, we investigated the gene structure distribution of the species-specific probes (i.e. monkey and mouse; Additional file 9). To test the significance of this probe distribution in monkey and mouse we compared the proportion of CpG loci that reside in each structure to the total number of CpG loci interrogated on the DNA methylation panel via permutation testing. We found that the optimization in both monkey and mouse is significantly biased (P < 0.0001) to retain more conserved gene structures (i.e. 5' UTR, 1 st exon, and gene body regions). This finding is consistent with the probe selection method used to optimize the assay, which requires that the species-specific probes be a near match to the human array (allowing for only a four base mismatch), meaning that conserved genomic structures are going to be preferentially retained and that the analyses of non-human genomes are going to be limited to these regions. Together, these data suggest that this optimization method is generalizable to any sequenced mammalian species, making genome-wide DNA methylation detection possible for a much broader group of species.
Novel utility of the array
The recent characterization of 5-hydroxymethylcytosine (5-hmC) in both stem cells and post-mitotic neurons, has led to a flurry of studies aimed to determine the role of this base in mediating epigenetic effects [8, [24] [25] [26] [27] [28] . While numerous recent methods have emerged that are capable of providing base-resolution of 5-hmC, these methods are sequencing-based, making them laborious and cost prohibitive [10, 11] . Thus, we sought to determine if the aforementioned human DNA methylation array (HumanMethylation450 BeadChips; Illumina), which is designed to detect 5-mC, could also report 5-hmC levels throughout the genome. To test this hypothesis, we treated human brain DNA with β-glucosyltransferase and recombinant mouse Tet1 (mTET), prior to following the standard array protocol (Methods), and found that replicates (N = 3) were highly correlated to each other, with R 2 -values similar to those found for 5-mC detection among human replicates (mean R 2 > 0.95; Figure 4A ). In comparison to the 5-mC levels in these samples (median = 53%), the median 5-hmC levels are much lower (21%), as the majority of the loci are < 40% 5'-hydroxymethylated ( Figure 4B ). Since independent analysis of 5-hmC (Methods) in these tissues validated the accuracy of the assay (Additional file 2H-M), these data suggest that this array is capable of providing a quantitative measure of 5-hmC throughout the human genome.
This finding prompted us to investigate whether the array could accurately detect 5-hmC in other mammalian genomes and we found that it provides a consistent quantitative measure of 5-hmC throughout both the monkey and mouse brain genomes (Additional file 8C-D); again suggesting that optimizing this assay is generalizable to any sequenced mammalian species. Comparison with the human 5-hmC profiles also revealed several interesting biological findings, including that 5-hmC profiles clearly distinguish between species (N = 8,189 probes; Additional file 8B) and that the primate median 5-hmC levels are highly correlated ( Figure 4C ). Thus, despite the fact that there are species-distinguishing 5-hmC marks, the majority of marks have a consistent level of 5-hmC, at least in primates ( Figure 4D ), suggesting that there is likely to be a significant overlap of primate genes with abundant 5-hmC levels. Consistent with this rationale, we found that primates indeed have a significant overlap of probes with > 20% 5-hmC levels ( Figure 4E ). In addition, primates have significantly more probes with > 20% 5-hmC than mice (53% (human), 42% (monkey), and 17% (mouse); Figure 4D ), suggesting that this mark may play a larger role in primates than mice. Together, these data show that this array-based assay has a broad utility in DNA methylation studies of both 5-mC and 5-hmC.
Hydroxymethylation and genomic context
The locations of methylated cytosines are often referred to with respect to either a CpG island or a gene. In regards to CpG islands, methylation is either on the island, on the island shores or on the island shelves (0-2 or 2-4 kilobases flanking the island, respectively; [29] ). Recent studies of 5-hmC in human embryonic stem cells (hESCs) have been contradictory regarding the 5-hmC level on CpG islands, with the most recent report showing that CpG islands are deficient of 5-hmC [10, 11, 25, 26, 30, 31] . However, studies of 5-hmC levels in mouse hippocampal and cerebellum tissue revealed that the prevalence of 5-hmC on a CpG island is determined in relation to the nearest gene, meaning 5-hmC is depleted on islands associated with a transcription start site (TSS) but enriched on intragenic islands [8] . To determine the distribution of 5-hmC relative to CpG islands in our human, monkey and mouse brain tissues we compared the proportion of CpG loci with > 20% 5-hmC that reside in or around CpG islands to the total number of CpG loci interrogated on the DNA methylation panel via permutation testing (see Methods). We found that all species have a significant overrepresentation of 5-hmC on the island shelves (P < 0.0001) and a significant underrepresentation on the islands (P < 0.0001; Figure 5A -E, Additional file 10 and Additional file 11). However, when the CpGs on islands were segregated into associated or not associated with a TSS, we found in all species that probes in islands associated with a TSS have a lower 5-hmC level (P < 0.0001). Together, these data show a consistent genome distribution of 5-hmC among species and support previous data from hESCs and mouse brain tissue, further validating this array for studies of 5-hmC.
Locations of DNA methylation relative to a gene refer to regions that include the distance to the gene TSS (TSS1500 (i.e. within 1500 bp of the TSS) and TSS200), 5'UTR, 1 st exon, body, and 3'UTR. Previous studies of 5-hmC levels in mouse hippocampal and cerebellum tissue revealed that 5-hmC is enriched in gene bodies [8] .
Here we found a similar enrichment in the gene body of all species (P < 0.0001) but our data also revealed that the 3' UTR has more 5-hmC than would be expected by chance alone (P < 0.0001; Figure 5F -K and Additional file 12). Since we also found a significant underrepresentation in all other genic regions (P < 0.0001), these data suggest that a non-stochastic mechanism may prevent 5-hmC from the 5' end of genes.
It is well known that specific regions of the genome are differentially methylated based on the biological functions of the genes contained within the region, with the most striking example being X inactivation in females. To determine if 5-hmC is specific to certain regions of the genome, we plotted the genomic locations of the 5-hmC and found that all three species have 5-hmC levels greater than 20% located throughout the genome, but closer examination suggest a deficit of 5-hmC on the X chromosome ( Figure 6 and Additional file 13). To test the significance of these observations and to determine if other chromosomes contain a disproportionate number of 5-hmC loci with levels > 20%, we compared the proportions of these 5-hmC loci for each chromosome using permutation testing (see Methods) and found that only humans have chromosomes with a disproportionate number of loci containing 5-hmC levels > 20%, both with deficits (X (P < 0.0001) and 18 (P < 0.03); Figure 6 and Additional file 11). Although the deficit on the X chromosome approaches significance in monkeys (P < 0.091), these data suggest that chromosomal deficits are human specific and that human chromosomes X and 18 are not governed by the same 5-hmC kinetics as the rest of the genome.
X-linked 5-hmC loci have functions in chromatin modifications and cell death
In humans the X chromosome was deficient of loci with high levels of 5-hmC. Annotation of X-linked CpG loci with > 40% 5-hmC in primates or > 20% in mice using gene ontology revealed several biologically relevant ontologies that were significantly overrepresented among all species. These findings predominately included terms associated with epigenetic functions including covalent chromatin modifications and histone acetylation. (Additional file 5; see Methods). Together, these data suggest that 5-hmC may play a role in an epigenetic feedback loop. Interestingly, annotation of the human X-linked CpG loci with > 60% 5-hmC using gene ontology revealed several biologically relevant ontologies that were significantly overrepresented for cell death and apoptotic processes, suggesting that 5-hmC may target a specific subset of genes on the X chromosome. Notably, gene ontological analysis of the entire array (N = 21,231 genes) also finds significant terms, suggesting that the full array may have a bias toward a subset of genes and that conclusions from ontological analysis should be taken with caution. Clearly further studies are needed to determine the diverse functional contributions of 5-hmC in the mammalian brain.
Discussion
This study optimizes an established human array-based DNA methylation (5-mC) assay to allow for accurate detection of 5-mC in non-human primates and mice and, perhaps more importantly, for the detection of genome-wide 5-hmC in mammals. Optimization of this assay dramatically improves its utility because now it can be used to simultaneously investigate genome-wide 5-mC and 5-hmC in any sequenced mammalian genome. Moreover, since the analysis of data generated by this array is well established, this assay will reduce the cost and time of DNA methylation studies, allowing for a greater utilization of mammalian model systems to investigate the role of epigenetics in mammalian biological processes. This optimization achieved high reproducibility among 5-mC data generated for chimpanzee, rhesus, and mouse by utilizing an approach that relied on filtering the data down to the probes with a near match (allowing for up to 4 mismatches) between the human genome and the species of interest. This filter for species-specific probes still provides data for > 90% of the human annotated genes in the monkey and nearly 25% for the mouse. Finding that the Figure 5 The distribution of DNA methylation with respect to CpG islands and gene structures. A-K) The density (y-axis) of probes at each methylation level (x-axis; beta) in human brain samples that were either interrogated for total methylation (5mc + 5hmc (black line)) or 5-hmC levels (5hmc (blue line)). A-E) Profiles shown are delineated for the island, the island shores (N_shore (5' end) and S_shore (3' end)) or the island shelves (N_Shelf and S_Shelf, which are defined as 0-2 or 2-4 kilobases flanking the island, respectively. F-I) Profiles shown are delineated relative to a gene, including the distance to the gene transcription start site (TSS; TSS1500 (i.e. within 1500 bp of the TSS) and TSS200), 5'UTR, 1 st exon, body, and 3'UTR. The number of probes is indicated for each island and gene category. chimpanzee analysis is able to retain far more probes (N = 360,491) is consistent with known evolutionary similarity with humans but also may reflect the higher quality reference sequence of the human and chimpanzee genomes compared to the rhesus genome. Recently, a similar approach identified 13,715 mouse-competent probes on the human array [32] , which contains nearly 75% of the mousecompetent probes reported here. Together these independent findings strongly support the use of this array with other species. The only other array-based method available for 5-mC detection in mice (Mouse CpG Island Microarray; AgilentTechnologies) relies heavily on the efficiency/reproducibility of restriction enzymes and the data is only reports 5-mC methylation at CpG islands, which our data here clearly shows is lacking the majority of the variable DNA methylation information ( Figure 5 ).
Having the ability to conduct an epigenome study in wide variety of sequenced mammals represents a significant new methodology. Here we compared the output of the optimized genome-wide array to that of a previously reported locus-specific study by Chiu et al., both investigating the epigenetic differences between monkey placenta and fetal tissue. Clearly the sheer magnitude of data from the array is not comparable between studies and neither are the conclusions. Notably, in 2007, when the Chui et al. study was conducted, the HumanMethylation450 BeadChips had not been developed; meaning Chiu and colleagues were using the molecular tools available at that time. This fact notwithstanding, while Chui et al. only found methylation differences in one of the nine interrogated genes (RASSF1), the much more comprehensive array approach developed here found differences in four out of the nine genes. In addition, the array identified differences in a total of 2,825 genes throughout the genome, including hypermethylated in cancer 1 (HIC1) and TIMP metallopeptidase inhibitor 3 (TIMP3), both of which were previously shown, using a locus-specific approach, to not be differentially methylated in normal placental tissue [33] . Together, these data highlight the dramatic advantage to using the array-based approach and suggest that studies of placental methylation need to be revisited.
It was previously shown that β-glucosyltransferase could be used to modify an existing array-based protocol for the detection of 5-hmC [34] . However, in that case the array was not specifically designed for methylation detection, the method relied on the efficiency/reproducibility of restriction enzymes, and the data was biased toward CpG islands. In contrast, using a modified protocol and the Human-Methylation450 BeadChip largely overcomes these limitations and produces a more reliable unbiased profile of 5-hmC throughout the genome, providing a new resource for epigenetic studies.
The density of 5-hmC probes in all three species profiles suggests that the bulk of 5-hmC levels are from 20% -60%, especially for primates ( Figure 4D ). While it was expected that the majority of probes would have a low level of 5-hmC (< 40%), we did not anticipate that, in the brain, nearly 50% of the primate loci would be > 20% hydroxymethylated and nearly 20% of human loci would be > 50% hydroxymethylated. These data suggest that 5-hmC is much more prevalent than previously reported and that it may play a more significant role in primates than mice. However, the gene ontological analysis suggests that this role is in a feedback loop for epigenetic processes such as histone lysine methylation and that these functions are common to all mammals.
In the brain tissues of all three species we found the distribution of 5-hmC with relation to gene structure to be consistent with previous reports that found 5-hmC is especially prevalent in the regions adjacent to CpG islands (in the shelves), indicating that the highest levels of 5-hmC are at regions of the genome with the lowest CpG density. Also consistent with previous work was the finding that 5-hmC is more prevalent in gene bodies compared to the 5' end of a gene; however, we find that the 3' UTR is particularly enriched for this mark, a location that may facilitate a proposed role in a epigenetic feedback loop. At the chromosomal level 5-hmC was reported elsewhere to be deficient from the X chromosome in mouse hippocampal and cerebellum tissue. In contrast, we didn't find a deficiency on any mouse chromosomes but we did find it is significantly deficient on the human X and approaching significance on the monkey X. Although the synteny between human and mouse X chromosomes is high, the smaller number of loci from the mouse may have resulted in a higher genomewide variance that precluded the mouse X data to reach significance.
As we learned with genome-wide association studies, successful epigenome-wide association studies of complex phenotypes are going to require the analysis of a very large number of individuals (N > 1000). The development of this assay improves our ability to quickly and reproducibly analyze the dynamic role of DNA methylation in a large cohort of individuals. This assay also augments the use of model systems for the study of epigenetic mechanisms and phenomena that are difficult to study in humans, including other recently identified modifications to methylcytosine, namely 5-formylcytosine and 5-carboxylcytosine. In addition, data from model systems will make it quite tempting to draw evolutionary conclusions between the different mammalian species and the gene ontology analysis shown here suggests that there are more similarities among species than differences. In short, this optimized assay holds great promise to improve our understanding of DNA methylation and its contributions to health, disease, and evolution.
Conclusions
Here we have developed an array-based assay to detect 5-mC and 5-hmC in mammalian genomes and show that it is generalizable to all mammals. Using this assay we find that placental tissue carries a cancer epigenetic signature, that 5-hmC has a hierarchical abundance among mammals, and that X-linked loci and the 3'UTR of genes have a heightened prevalence for 5-hmC. In short, this optimized assay greatly improves the utility of mammalian model systems for studying the role of epigenetics in human health, disease, and evolution.
Methods
Tissue acquisition and DNA extraction
Except for the mouse brain tissues (UW IACUC protocol #M02529), all other tissues were supplied by other research groups, including monkey skin and brain tissue (Dr. Kalin's group; UW IACUC protocol #G00181), monkey placental and fetal tissue (Dr. Golos' group; UW IACUC protocol #G00245), and human brain tissue (Emory Neuroscience NINDS Core Facilities; approved by the Emory Internal Review Board on August 18, 2013 and given the approval number CR2_IRB00045782). All groups follow animal housing and experimental procedures that are in accordance with institutional guidelines. Once acquired, approximately thirty milligrams of tissue was homogenized with glass beads (Sigma) and DNA extraction was performed using AllPrep DNA/RNA mini kit (Qiagen).
DNA methylation profiling
Genomic DNA was split into the following two aliquots: a sodium bisulfite-only (SB-only) aliquot; and a Tet1 treated followed by SB treated aliquot (TAB). The Tet1 treatment was conducted using previously described methods [11] . Briefly, one microgram (μg) of genomic DNA was spiked with four nanograms (ng) of synthetically methylated control DNAs (N = 3). Together, these DNAs were sonicated to 400 basepairs (bp) using a Diagenode Bioruptor Plus (Diagenode) and concentrated to 19 μl (Amicon Ultacel 100 k, Millipore). To mark 5-hmC, the concentrated DNA was then glucosylated with T4-β-glucosyltransferase (1 μM; Wisegene) and UDP-glucose (200 μM, Wisegene) at 37°C for 1 hour, and purified using the QIAquick Nucleotide Removal Kit (Qiagen). To mark 5-mC, five hundred ng of the glucosylated DNA was oxidized in the presence of recombinant mouse Tet1 (0.48 μg/μl; Wisegene) at 37°C for 1 hour followed by enzyme inactivation with protease K at 50°C for 1 hour. The oxidized DNA was twice purified (Micro Bio-Spin 30, Bio-Rad; QIAquick PCR Purification Kit, Qiagen) and eluted in 20 μl of water. SB-treatment of both aliquots: Five hundred nanograms of genomic DNA or Tet-treated DNA was sodium bisulfite-treated for cytosine (C) to thymine (T) conversion using the EZ DNA Methylation-Gold kit (Zymo Research). The converted DNA was purified and prepped for analysis on the Illumina HumanMethylation450 BeadChips following the manufacturer's guidelines. Briefly, converted DNA was amplified, fragmented, and hybridized to the HumanMethylation450 pool of allele-differentiating oligonucleotides. After a series of extension, ligation, and cleanup reactions, the DNA was labeled with a fluorescent dye. The labeled DNA was then scanned using an Illumina BeadArray Reader or iScan. Image analysis and signal determination were performed using the GenomeStudio software, Methylation Module (Illumina).
Interpretation and QC of DNA methylation data
CpG DNA methylation data were interpreted using Geno-meStudio to quantify methylated (M) and unmethylated (U) signal intensities for genomic DNA. The signals were quantile normalized, and overall methylation levels (β) were calculated as the ratio of methylated to total signal [i.e. β = M/(M + U + 100)], where β ranges from 0 (unmethylated) to 1 (methylated). For human samples, quality control of data resulted in removal of samples with aberrantly low signal intensity (mean < 2000) or with fewer than 99% of CpG loci detected, where a given locus was deemed not detected if the detection P-value was > 0.01 (detection P-value provided by Genome Studio and calculated relative to background signal). For rhesus, chimp and mouse samples, the data for only the 'competent' probe-set (ref. section ' Assay optimization') for each species was taken. Furthermore, any probes having more than 20% of samples with detected P-values > 0.01 were discarded from the analysis. Assay controls were inspected to remove samples with poor bisulfite conversion, staining, extension (single nucleotide extension assay), hybridization, or specificity. Outliers identified by hierarchical clustering and/or dissimilarity matrices were removed. Additionally, one control DNA replicate was run on each BeadChip to assess overall assay reproducibility. Methylation profiles of the control DNA correlated well, with an average Pearson correlation coefficient (R) of 0.990 between human replicates.
Analysis of cancer-associated CpG loci
To analyze DNA methylation differences associated with cancer, we fit a separate regression for each CpG site. Although samples were randomly distributed across Bead-Chips and experiments with respect to disease, BeadChip was also included as a random effect covariate in all analyses to account for potential batch effects. The package "nlme" in R (Cran) was used for the mixed effect model. Fixed effects included intensity in the model. To correct for multiple hypothesis testing, we applied a Benjamini-Hochberg False Discovery Rate (FDR) correction using the R function "p.adjust," but to avoid false positives due to the small sample size, we used conservative Bonferroni adjustment for our ultimate determination of significance.
Permutation analyses for rhesus differentially methylated loci
All permutation analyses were conducted in R using the same linear model as the actual analysis, where Bead-Chip was treated as a mixed-effects covariate, but in each permutation the tissue type of the sample was randomly reassigned. In total, 100 permutations were conducted. Permutation P-values for each CpG locus were calculated by assessing the number of times each locus was more significantly associated with fetal tissue in the 100 permuted data sets than the actual.
Analysis of genomic location
Loci were mapped to chromosome location using the Illumina annotation files for the HumanMethylation450 panel based on the NCBI Human Genome (build 37). Over-and underrepresentation of CpG loci with > 20% median 5-hmC were assessed using both Fisher's exact test and permutation analysis, which corresponded well (data not shown). Permutation P-values were determined as described previously [16] , by comparing the proportion of >20% 5-hmC loci on a chromosome (termed "actual proportion") to the proportions obtained using the permuted loci (termed "permuted proportions"). To correct for multiple hypotheses (i.e. 24 chromosomes and both over and underrepresentation) the actual proportion of each chromosome was compared to the permuted proportions of any chromosome for each permutation. Thus the permutation P-value is the number of times a permuted proportion is more significant than the actual proportion, divided by the number of permutations (10,000).
Data access
We have submitted the data generated from the monkey, chimp, human and mouse samples for this study to the Gene Expression Omnibus (GEO), which can be found under the Gene Series: GSE49177.
(5hmc_Rhesus_Mismatch_pvalues_Ch; tab 5), and mouse (5hmc_Mouse_Mismatch_pvalues_Chr; tab 6). All of the pages in this file have the following header descriptions: a genomic description of the locus location (Region (tabs 1-3); Chromsome (tabs 4-6)); whether the data is filter for probes > 20% or > 40% 5-hmC (Cutoff); the total number of probes in the dataset (NumProbes_Dataset); the number of probes after the filter has been applied (NumProbes_Cutoff); the number of probes in the genomic description of interest (NumProbes_Region or NumProbes_Chr); the number of probes that meet the genomic description and the filter criteria (NumCommonProbes); the Fisher's exact test P-value (FisherPvalue); the odd ratio for the result (OddsRatio); and the permuted P-value (PermPvalue). The tabs showing the chromosomal analysis also have a column that shows the variance that the data has for each chromosome (Variance). See text for definitions of the regions.
